Avant Labs LipoDerm-Y

LipoDerm-Y is the most significant breakthrough in fat loss products to date. Containing the alpha 2 receptor antagonist Yohimbine Hydrochloride in Avant Labs’ Patent Pending hydroalcoholic gel, Lipoderm-Y releases large amounts of fat from the site(s) of application—far higher than is possible with alternate administration methods—while avoiding the negative side effects associated with systematic distribution. Coupled with a caloric deficit, Lipoderm-Y ‘s targeted delivery accelerates localized fat loss in those typically stubborn areas, such as a woman’s lower body or a man’s midsection. Lipoderm-Y makes what was once the myth of “spot reduction” a scientifically-proven reality.

Each 4oz bottle contains 18-30 applications, with 3 grams of Yohimbine HCl per bottle.



I have previously stated that I believe transdermal prohormones to be the most effective supplements ever to hit the market. That statement must now be amended. Transdermal prohormones are indeed the most effective MUSCLE BUILDING supplements ever to hit the market. But, topical fat loss products have the potential to be an even bigger overall breakthrough in the never ending quest to improve body composition.

There are four areas that need to be addressed in regards to topical fat loss products and so called "spot reducers" in general. First, one needs to distinguish between the products that are merely diuretics and those that the manufacturer (assuming they have a brain) actually thinks might significantly reduce body fat. Second, we have to have an understanding of the andrenergic system, which is primarily what these products attempt to manipulate in order to aid lipolysis Thirdly, we must have an understanding of transdermal/percutaneous delivery, in order to understand why a topical formulation could present advantages vs. orals, as well as to understand why every product of this kind currently on the market, other than LipoDerm-Y, fails. Within this category there are 2 issues -- getting adequate amounts past the skin barrier and localizing its distribution to adipose tissue. And, finally, there is the issue of Yohimbine HCl vs. yohimbe. After reading this, you should have an understanding of why true "spot reduction" is physiologically quite possible, as well as enough information to make an informed decision as to which products can and cannot accomplish it.

Fat Loss Agents vs. Diuretics
Assuming we are not preparing for a photoshoot or competition, a product that merely acts as a diuretic rather than significantly aiding actual lipolysis is basically worthless. "Cutting Gel" belongs in this category -- its active ingredient is aminophylline:

Aminophylline is a xanthine derivative, similar to caffeine, which is not a particularly potent fat burner. In rat studies, it has shown good thermogenic properties due to blockade of adenosine receptors (which provide one of the negative feedback mechanisms for catecholamine induced thermogenesis) and inhibition of phosphodiesterase (which degrade cyclic AMP) -- but this is at extremely high doses, which would kill a human, so it is not applicable (1,2). At therapuetic doses, only adenosine blockade occurs, which will act to increase norepinephrine levels (3)-- but as you will see norepinephrine stimulates alpha 2 receptors (bad) in addition to beta 2 receptors (good) -- and in stubborn fat, alpha 2's outnumber beta 2's (4).

Like caffeine, it is a good diuretic (5), which would account for the girth loss in the study they reference, which did not measure actual fat loss (6,7). One study did look at fat depth after use of an aminophylline cream, and no difference was found vs. control (8). As a local diuretic, it might be effective, but as a true fat loss agent, it quite likely is not.

Precontest, such a product could be extremely beneficial if it would truly localize the water loss, as it would allow one to get rid of extracellular water with out the total body dehydration produced by drugs such as Lasix -- thus, one could have fuller muscles, less cramping, etc. I am not particularly familiar with the physiology of diuresis, as I have not researched it to any great extent, so I don't know if it could actually be localized.

Products such as LipoDerm-Y, Impact's DermaLean, and S.A.N.'s LipoBurn (basically any of the products with yohimbine and a handful of other ingredients) fall into the latter category. They are intended to manipulate the adrenergic system, thus, theoretically, such products could cause true localized fat loss if formulated properly:


Introduction
One of the major contributors to body weight homeostasis in the human body is the adrenergic system. There are two types of adrenergic receptors, alpha and beta, as well as subtypes of each -- and depending on which are activated, lipolysis (breakdown of fat) can be either stimulated or inhibited.
The most well-known adrenoreceptors to bodybuilders are the beta receptors. These can be divided into subtypes 1, 2, and 3 -- and it is through these receptors that drugs such as the ephedrine/caffeine stack and Clenbuterol exert their effects. While Clenbuterol acts directly on beta 2 receptors, ephedrine exerts its effects indirectly by stimulating the release of norepinephrine (NE), the body's primary endogenous thermogenic hormone. Unlike Clenbuterol, NE is not selective in its binding. In addition to binding to the beta 2 receptor, it also binds to both alpha receptors, as well as the beta 1 and 3 receptors. It is in regards to its binding to the alpha 2 receptor that yohimbine comes into play.

Norepinephrine and Yohimbine
Activation of the alpha 2 receptor inhibits the release of NE. Thus, by binding to this receptor, NE functions as its own negative feedback signal. In other words, it shuts off its own release. Obviously, this is not a good thing for fat loss. This is particularly true at rest (which, unless you are a marathon runner is 95% of your day) -- this is because alpha 2 receptors are activated at lower catecholamine levels than are the beta receptors (9). Thus, thermogenesis is basically always turned off. It is the differences in regional distribution of alpha 2 and the beta receptors that is responsible for the gender differences in bodyfat storage (4). Basically, females have a large number of alpha 2 receptors and few beta receptors in the gluteofemoral area (hips, thighs, and butt), while men have the same problem in the midsection. With exercise or the use of compounds such as the ephedrine/caffeine stack, catecholamine levels can be increased to a point where the alpha 2 induced inhibition of lipolysis is partially overcome (9). However, even then, the alpha 2 receptors ARE still acting to reduce lipolysis.

Yohimbine is a selective alpha 2 antagonist (10) and can thus short circuit this feedback loop, maximizing NE levels, thus maximizing fat loss, particularly in these problem areas -- and even more so if we can achieve high levels of yohimbine and NE in the adipose tissue. Unfortunately, to do so with orals, or any other method that results in high blood levels means that we will also have high levels in the heart and CNS -- thus, we will also have unpleasant and dangerous side effects. Considering the subject of this article, I obviously believe the solution lies in transdermal administration, but more on that in a bit.

Blood Flow
A second, more indirect, mechanism by which Yohimbine can aid lipolysis via the adrenergic system is by increasing peripheral blood flow (11, 12). Adipose tissue is known to have rather poor vascularity. When triglycerides are broken down into free fatty acids and glycerol during lipolysis, they must also be transported away from the fat cell or they risk being reincorporated into adipose tissue. Beta receptor activation causes vasodilation, thus increasing blood flow, however, it does not increase enough to remove all of the free fatty acids released during lipolysis (13). Alpha 1 and 2 receptor activation, on the other hand, causes a decrease in blood flow (4, 14). Thus, antagonism of the alpha 2 receptor with yohimbine would be expected to increase blood flow, and thus increase the mobilization and disposal of these FFA's, further aiding fat loss. And, again, the more we can get in the adipose tissue without it reaching the heart and CNS, the better.

Percutaneous Delivery
Though the terms are often used interchangeably in the literature, there are two distinct forms of drug delivery through the skin. The first, and most common, is "Transdermal Delivery" -- this involves a drug bypassing the skin barrier in order to be taken up into the bloodstream and distributed systemically (15). This basically does the same thing as oral delivery, but it is inherently time released and avoids first pass metabolism in the liver which can limit bioavailability and cause hepatotoxicity, so it is is advantageous for delivering many drugs.

The second is "Percutaneous Delivery" (15)-- with this method, one bypasses the skin barrier, but with the purpose of delivering the drug to specific target tissues in the body, while AVOIDING uptake into the blood and subsequent systemic delivery. In the pharmaceutical realm, this has been pursued primarily for antibiotics and NSAIDS -- the former, to avoid destruction of systemic microflora (so-called "good bacteria"), and the latter to avoid hepatic recirculation, which is responsible for gastrointestinal problems.

Unfortunately, the people who have developed most of the topical fat loss products thus far either do not know about or understand this difference or they do not understand its paramount importance in regards to adrenergic modulators such as yohimbine. With prohormones, systemic uptake and distribution is our goal -- they have poor oral bioavailability, so we are just trying to avoid the liver in order to get significant amounts in the bloodstream.

However, with yohimbine and other adrenergic agents, oral bioavailabilty is not the issue -- at about 22%, it is more than adequate (16). We can readily achieve adequate blood levels with oral usage. The issue with these is that as we increase dosages (and thus blood levels) in order to increase distribution to adipose tissue to aid fat burning, we also increase distribution to the heart and CNS where we create numerous unwanted side effects such as rapid heart rate, high blood pressure, and overstimulation, which is particularly noticeable with exercises. Yohimbine is also used clinically to produce anxiety (17). Ideally, we want our drug to reach fat cells in high doses, without the dangerous side effects of high levels in the heart and central nervous system.

So, how do we do this?? Unfortunately, it is easier said the done. Typically, drugs that penetrate the skin barrier and traverse the epidermis and dermis are rapidly taken up by the dermal microvasculature, where they are delivered systemically (just like with orals) -- this is well characterized in the literature (15,18,19) -- with direct tissue penetration being limited to 1-4 mm, which obviously is not exactly deep into the adipose tissue. And, considering that these substances have good oral bioavailability, if the dermal microvasculature is not taken into account, we end up with a product that not only does not localize delivery, it does not even deliver it systemically as efficiently as an oral would do. Considering these products cost far more than there oral counterparts, and could also be thought of as inconvenient in that you have to rub them on your body, any supplement developer who doesn't take dermal uptake into account has obviously missed the boat quite badly. And, guess what... Not one single product other than LipoDerm-Y does. And guess what else -- they probably are not going to because we have filed a use patent on the one carrier that has been shown in the literature to effectively accomplish this.

Targeted Delivery
Let's now take a look at the literature that supports the idea of tissue specific delivery of therapeutic substances. As mentioned previously, when it comes to targeted delivery, the pharmaceutical realm, and thus the literature, has primarily concerned itself with antibiotics/anti-fungals and NSAIDS. We will look at the three most important ones.

Editors note: I am not going to give the name of the substance that has been shown to be effective as a vehicle for local delivery at this time. I may do so when the product comes out, as it has to listed on the label. Though we have filed a patent on it, there are many companies whom that will not stop from attempting to steal our intellectual property. They lack the intelligence and creativity to discover this sort of thing on there own (as well as the integrity to think such things matter) so they choose to make their money in this manner.

The first study (19b) involved the NSAID indomethacin as the drug to be delivered. The drug was given orally (O) , topically without the "special delivery solvent" (WO), and with the "special delivery solvent" (W). The topicals were applied to the shoulder. For the first two hours after administration, concentrations of the drug in the deltoid (which is obviously even deeper than adipose tissue) were 5 times higher in W than in either O or WO. After 4 hours, it was 3 times as high, and by 8 hours it was still twice as high. Obviously, the formulation containing the "special delivery solvent" was vastly superior at delivering the drug to the target tissue. But what about delivery to unwanted tissues? If it was just a case of the "special delivery solvent" allowing more drug to cross the skin, this would not be a big deal -- we could just use more. What we also need is for a minimal amount of the drug to be delivered systemically, and once again, the "special delivery solvent" was shown to be superior. Maximal blood levels of all three compounds occurred at the 2 hour mark. W displayed levels about 1/3 that of O and 1/2 that of WO.

If the significance of this is not clear, it basically means that localized delivery (what we want) per unit systemic delivery (what we don't want) for W was 15 times that of O and 10 times that of WO -- and this was to the muscle. Considering the adipose tissue is closer to the skin (which had levels 10 times as high as the muscle) and that the joint capsule (which is below the muscle) had levels 1/3 that of the muscle while with WO there were equal levels at the muscle and joint, the ratio of delivery to adipose tissue vs. systemic delivery for W is likely significantly higher.

The second study (19c) utilized the antibiotic erythromycin as the delivery drug. Formulations for W and WO were identical to the above study. Oral administration was not tested. Exact counts of the concentration in muscle tissue was not reported, but the authors stated that after 4 hours, there was a major increase in the muscle mass below the site of application (I have contacted the authors to try to get exact data). Kidney and liver levels (indicative of systemic distribution) were significantly lower for W than WO -- about 1/2 for the former and 1/4 for the latter over 24 hours.

The third study (19d) we will look at utilized the antifungal griseofulvin as the delivery drug and compared W with oral intake. The formulation for W was the same as the previous two studies. The accumulation of the active compound in the area of application for W was several hundredfold greater than that which accumulated in the organs, and brain levels were non-detectable, which is extremely important considering we are trying to avoid excessive CNS stimulation -- and all of this was a full four days after application. Compare this to oral delivery which showed concentrations that were approximately identical in all areas, which would be expected if systemic uptake occurred.

Penetration Enhancement
I think it should be clear from the previous studies that it is quite possible to achieve targeted delivery. However, if we cannot get adequate amounts of our substance past the skin barrier, it is a mute point. And, considering one of the skin primary purposes is as a water barrier (20), hydrophilic substances such as yohimbine do not readily pass through (21, 22,23). Thus, we need to turn to the topic of penetration enhancement (for a more thorough presentation, see my previous article Transdermal Delivery.

Yohimbine HCl, with a LogP of about .75 (24), is fairly polar/hydrophilic, thus penetration enhancers should be chosen accordingly -- namely we want those which affect the polar route. This rules out many commonly employed penetration enhancers -- a fact many companies do not seem to be aware of. Since there is very little direct data on penetration enhancement with Yohimbine HCl, we will look at data when substances with similar physical properties were used.

One promising chemical in this area is the terpene, l-menthol. Polar molecules undergo significant hydrogen bonding in the stratum corneum, which is the primary reason for their poor passage through the skin barrier (23). Because of the presence of a hydroxyl (OH) group, l-menthol should bond to these hydrogens (25), leaving our drug free to more easily traverse the skin barrier. And, indeed the data has supported this. It increased the permeability coefficient of mannitol 100 fold vs. control (26). In a study using Propranolol HCl which has a partition coefficient almost identical to yohimbine (Log P .74 vs. .75), it increased flux 1000 fold vs. control and also displayed the shortest lag time of all terpenes tested (25). This is in contrast to d-limonene, almost identical, structurally, to l-menthol, with the exception of lacking the afore mentioned hydroxyl group, which has been shown to much less effective for polar compounds (25, 27).

A second chemical is laurocapram. It too has been shown to be quite successful with polar drugs (23,28,29) likely due to its increasing the water content of the lipid phase of the stratum corneum. In one study, it enhanced the flux of mannitol in a propylene glycol vehicle by over 350 fold (23). Unfortunately, it displays a significant lag time -- meaning it can take as much as 10 hours before it starts to work (30, 31, 32). Consider most of us shower daily, this is not acceptable.

That brings us to n-methyl-2-pyrrolidinone (NMP). In combination with laurocapram, in a study using morphine hydrochloride, which has physical properties similar to Yohimbine Hydrochloride -- both polar molecules, molecular weight of 322 vs. 390 -- and is thus quite applicable, NMP was shown to significantly reduce the lag time (down to as low as 2 hours) as well as increase the rate of penetration for the drug as indicated by blood levels that were several thousandfold high than controls (32). In addition, it has been shown in several other studies to enhance penetration of polar molecules on its own, including a 256 fold increase with mannitol (23).

Finally, we have also added glycerol, which provides dual functions. First, it helps to counter any skin irritation that might be caused by the alcohol carriers. This is due to its increasing the water content of the skin, and as alluded to in regards to laurocapram, this increase in water content has the added bonus of increasing penetration for polar molecules such as yohimbine (33, 34).

Yohimbine vs. yohimbe
Quite a bit of confusion seems to exist about the difference between Yohimbine and yohimbe. Yohimbine is the principal alkaloid from the herb P. yohimbe. However, there are 31 other yohimbane alkaloids that can be present in herbal yohimbe preparations. Some of these have different and unknown selectivities and potencies (and thus, effects) at the adrenergic receptors (35, 36) -- in addition, these preparations vary greatly from brand to brand and even from batch to batch, as no standardization for extraction exists. In fact, a recent investigation found that most over the counter preparations have little to no actual yohimbine (37). And, even in the more potent preparations, most people find a higher degree of undesirable effects with the herb vs. pure Yohimbine (due to the afore mentioned 31 other yohimbane alkaloids that can be present). With LipoDerm-Y, you are guaranteed 25mg of pure, pharmaceutical grade Yohimbine HCl per milliliter, without the added side effects from other alkaloids - thus, allowing safer, more reliable dosing.

Dosing
Because some people are unusually sensitive to yohimbine, I would recommend that one start with a small dose -- 3-4 squirts (50 mg) and then increase the dosage by 25-50mg each day until side effects become unacceptable. Dividing it into two doses would be ideal, but probably not necessary. In our beta testing, we have gone as high as 400mg/day without significant side effects. I have personally done this along with an EC stack, and the only time side effects were particularly noticeable was during workouts.

Another thing to be considered when using yohimbine is that insulin blunts its lipolytic effects. Because yohimbine is not reaching the pancreas in significant amounts as it would with oral administration, insulin levels will not be as high for a given amount of carbohydrates, but they will still be elevated. Thus, it should ideally be used on a low-carb/ketogenic diet, or at the very least, one should do moderate aerobic activity for an extended period first thing in the morning on an empty stomach.

Conclusion
I think it should now be exceedingly clear that all topical fat loss products are not created equal -- and you should now be equipped to make an informed decision on which one to use. To sum up:

• The formulation should contain active ingredients that are significantly lipolytic rather than mere diuretics.
• The formulation should use yohimbine hydrochloride rather than the yohimbe herb.
• The formulation must not only include penetration enhancers, but they must be appropriate for polar a molecule.
• The formulation must avoid uptake by the dermal microvasculature or it will merely be an expensive, inefficient version of a pill.
• The formulation that meets these criteria is LipoDerm-Y.

Indredients:
Isopropyl alcohol, benzyl alcohol, water, n-methyl-2-pyrrolidinone, glycerol, l-menthol, laurocapram, Carbomer 934.

Directions:
For topical use, apply gel onto dry, clean skin, in any areas in which fat loss is desired. Most effective for hips, buttocks, and thighs in women, and the midsection in men. Allow 1-5 minutes to dry. Each six squirts (4 ml) contains 100mg of Yohimbine HCl. Start with 3-4 squirts and increase daily. Stop if side effects become apparent. Do not exceed 10 squirts at one time. Do not exceed 20 squirts in one day.

WARNINGS:
FOR EXTERNAL USE ONLY. Harmful or fatal if swallowed. Keep out of reach of children. In case of accidental ingestion, seek professional assistance or contact a poison control center immediately. If excessive irritation of the skin developes, discontinue use. Avoid getting in eyes or mucous membranes. This product contains yohimbine, which must not be used by children, geriatrics, pregnant women, or those with or predisposed to high blood pressure or any cardio-vascular problems. Do not use with alcohol, mood-altering drugs, or anti- depressants. Do not combine with ephedra or any other stimulants. If high blood pressure or rapid heart rate is noticed, discontinue usage.

Additional Info:

S u p p l e m e n t F a c t s Serving Size: 1/2 to 1 Tsp Servings Per Container: 18-30 Amount Per Serving % Daily Value Yohimbine HCl 166mg to 100mg † * Percent Daily Values are based on 2,000 calorie diet. † Daily Value not established.

Q: Spot reducing is a sham. Don’t we all know that?
A: This is the typically espoused assumption, and is in most cases correct. When one consumes less calories then one’s body burns, a caloric deficit is created which your body must make up for. The human body typically combats this deficit through an increase in lipolysis (fat burning). Due to many genetic and hormonal variations, fat may not be lost in a proportional manner; that is, one may lose more weight from one’s arms and legs than one will from his or her abs and hips.

Even so, when any type of significant lipolysis occurs, the body is in a manner “spot reducing.” Several areas on the body experience a decrease in girth in response to caloric deficit. This “spot reduction” is an effect, not a cause. The misconception regarding “spot reduction” largely originates from the fact that most assume this to mean the elimination of fat from a given area with the use of a magical crème which initiates lipolysis WITHOUT caloric deficit, or the use of toning exercises erroneously believed to reduce fat concentrations in a specific area. This is simply not possible.

There can be no spot reduction without caloric deficit. The problem in the past has been that we have had very little control in determining the areas from which the body will preferentially burn fat. As already established, caloric deficit alone will result in lipolysis, though its effects will be experienced to a greater degree in some areas (“spots”) as opposed to others. Control of this process has in the past been largely beyond our reach.

With the exception of the topical Yohimbine HCl products that have preceded Lipoderm-Y, these topical “fat burners” failed to address the issue of systemic uptake (overall distribution into the blood stream), and were nothing more than diuretics. Unlike the false claims put forth by the manufacturers of these diuretic agents, Lipoderm-Y does not pretend to generate a controllable spot reducing effect without a concurrent caloric deficit.

As opposed to internal events dictating the origin of the fat stores to be released and burned for fuel, this process can now be largely controlled externally with Lipoderm-Y; it will release fat from the site of application and allow a degree of control over the patterns in which fat loss will occur.

Instead of reducing your calories, and then internally waiting for your body to release fat from those “trouble spots” which are reluctant to let go of adipose tissue, Lipoderm-Y releases the fat from the site(s) of application, and when combined with a caloric deficit, results in the effective realization of controllable “spot-reduction.”


Q: How should LipoDerm-Y be taken?

A:

1. Lipoderm-Y should be taken two times per day with 12 hours separating application times.
   
   
2. Lipoderm-Y should be used at least 2 hours before any activities in which one will sweat or expose the skin to significant amounts of water, due to the risk of the product washing off before it firmly binds with the skin.
   
   
3. Apply to one large area at a time, or several small areas at a time. The dieter can only utilize so many of the stored calories being released via LipoDerm; if an excess is released, those calories will not be burned but simply redeposited. *An example of a “large” area is the thighs/hips/buttocks or the abs/lower-back/obliques (or any combination thereof).

Q: It is recommended that one should optimally use LipoDerm-Y with a caloric deficit of 500-1000 calories. This is 500-1000 calories below one’s daily total maintenance intake—activity levels included—and not one’s Resting Metabolic Rate (RMR) correct? I.e., my maintenance level is around 2040 for my weight, but after working out three days a week and cardio 2-3 days a week, it's actually closer to 3040 a day.
A: Correct.


Q: Is LipoDerm-Y allowed in drug free competitions?
A: Is Yohimbine allowed? If so, then there should be no issue with the use of Lipoderm-Y.


Q: Should I cycle this, and how long should a bottle of LipoDerm-Y last?
A: The only reason to cycle, other than financial constraints, would be the possibility of alpha 2 receptor upregulation. No one has reported fat returning upon cessation of use, so this is probably not much of a concern. 5 squirts 2 times per day, and 10 squirts 2 times per day, will last 36 and 18 days respectively.


Q: I have heard that Yohimbine HCL can cause water retention. If I use Lipoderm-Y, how many days out from a contest should I discontinue use so I don't hold water?
A: One week should suffice, though with use of a diuretic, this time could be reduced. Preparation-H Gel, used after the cessation of LipoDerm-Y usage, can expedite the removal of water and allow for a more rapid evaluation of Lipoderm-Y’s results.


Q: Can I increase my dosage of LipoDerm-Y, above the recommended amounts?
A: You can do this, but you must keep in mind that Yohimbine’s primary function is the mobilization of fat; it does not cause a significant increase in total amount of fat burned (compared to something like DNP). Thus, the more LipoDerm-Y one uses, the more one is required to reduce calories for said dose to be truly effective.


Q: When is the best time to apply LipoDerm-Y given that I consume a post workout shake (insulin spike etc)?
A: Due to Lipoderm-Y’s delivery method, Yohimbine HCl is gradually released into your system, so the timing of the application is irrelevant regardless of your training and diet schedule. Simply apply twice daily with 12 hours separating each application. .


Q: Is it possible to stack Lipoderm-Y with ECA or NYC? What is the best approach in these regards?
A: If one is supplementing with LipoDerm-Y, ECA would be a better option than NYC since Lipoderm-Y already delivers high amounts of Yohimbine HCl in a site-specific manner. ECA will elicit a far greater increase in NE, and combined with the Alpha-2 blocking of Yohimbine, one should obtain better results than would be offered by the coupling of Lipoderm-Y with NYC.


Q: I have heard that Yohimbine HCl can cause High Blood Pressure. Per 6 squirts, your product contains 100 mgs of Yohimbine. Isn’t this dangerous?
A: Oral and topical (percutaneous in this instance) delivery of Yohimbine elicit significantly different effects. Orally, one is primarily going to receive Yohimbine’s stimulatory effects, with the blocking of A2 receptors in other tissues being secondary. With LipoDerm-Y, unlike with oral administration, one bypasses systemic distribution and primarily targets the adipose tissue, chiefly blocking the A2 receptors in the area of application only. This delivery method minimizes Yohimbine’s stimulatory effects, thus allowing for a far greater amount to be used.


Q: As is often recommended with oral Yohimbine, must I use LipoDerm-Y with a Ketogenic diet? If not, what type of diet would be ideal?
A: Oral Yohimbine blocks the pancreatic A-2 receptors, increasing the response of Insulin in the presence of carbohydrates; this is one reason it is often recommended that it be used in conjunction with a Ketogenic diet (or at the very least be reserved for use before low-carbohydrate meals). This is not the case with LipoDerm-Y however, again due to its percutaneous delivery method. A caloric deficit is all that is required for Lipoderm-Y to work; the dietary method by which this deficit is achieved is of secondary concern.


Q: Can I use any of your other topical gels in addition to LipoDerm-Y?
A: Yes, one can use any of our other topical gels and LipoDerm-Y simultaneously. The only requirement when using two such products is that they not be applied to the same area.


Q: What other supplements can be added to impart a synergistic effect with LipoDerm-Y?
A: Other than an ECA stack, Sodium Usniate/Usnic Acid can be put to use, as the uncoupling activity of SU/UA will aid in mobilizing fat, further enhancing Lipoderm-Y’s effects.